Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.37 |
| ▸ | SCN4A | P35499 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482897 | 0.90 | ADRA2A (0.37) | CYP19A1NR3C2SCN4ASLC6A2SLC6A4 | |
| SCHEMBL8035364 | 0.82 | IDO1 (0.36) | CYP19A1SLC6A2SLC6A4SLC6A3IDO1 | |
| SCHEMBL10549653 | 0.82 | CYP19A1 (0.43) | CYP19A1NR3C2ESR1 | |
| SCHEMBL32672719 | 0.81 | ADRA2C (0.37) | CYP19A1NR3C2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL32672752 | 0.81 | ADRA2C (0.37) | CYP19A1NR3C2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10547608 | 0.80 | CYP19A1 (0.42) | CYP19A1ESR1 | |
| SCHEMBL1484177 | 0.80 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3TAAR1MAOA | |
| SCHEMBL1482968 | 0.79 | IDO1 (0.32) | CYP19A1SLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL1483042 | 0.79 | IDO1 (0.35) | IDO1 | |
| SCHEMBL32673000 | 0.79 | ADRA2A (0.38) | SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735438-B2 | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735438-B2 | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20110077274-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077274-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-7902247-B2 | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902247-B2 | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors | ALLERGAN, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2009089132-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090176843-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090176843-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077274-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ADRA2C, ADRB3, ADRB2 | CYP19A1 1761/4885NR3C2 62/4885SCN4A 212/4885 |
| US-20090176843-A1 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ADRA2C, ADRB3, ADRB2 | CYP19A1 1734/4885NR3C2 57/4885SCN4A 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.